Oncotarget

Exploring a rare case of a 15-year-old boy with Intrathoracic Synovial Sarcoma and BRAF V600E mutation, showcasing the benefits of molecular testing and targeted treatment with a BRAF inhibitor for better patient outcomes

The podcast explores the crucial role of Ras in cancer development, focusing on how inhibitors can target Ras mutations in pancreatic, colorectal, and lung cancers. Advances in engineering Ras binders using protein scaffolds, experimental evolution, and computational techniques are highlighted for more effective treatment. Intracellular protein delivery techniques like fusion with CPPs and nanoparticle coupling offer innovative strategies for precise Ras inhibitor delivery in cells, enhancing targeted cancer treatments.

Exploring the use of cetuximab with radiotherapy for locally advanced cutaneous squamous cell skin cancer, with high response rates and minimal toxicity in a retrospective study of 18 patients.

Experts discuss how preoperative hydroxyprogesterone may improve survival in breast cancer patients by modulating cellular stress response and inflammation. The role of progesterone in overcoming endocrine resistance is highlighted, along with the significance of non-coding RNAs and the SGK1/AP-1/NDRG1 axis in this process.

Researchers discuss the transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors using Nerofe and Doxorubicin. These drugs target KRAS mutations and show promising results in colorectal cancer by downregulating KRAS signaling and enhancing immune response activation.

Researchers discuss the role of ERβ in inflammatory breast cancer, highlighting its significance as a potential tumor suppressor and its implications for treatment outcomes in this rare and aggressive form of breast cancer.

Delve into the dark and bright sides of PLK1 in tumorigenesis as researchers unveil a novel GEM model to study its oncogenic potential. Learn how abnormal PLK1 expression contributes to chromosomal instability and potential therapeutic opportunities for targeted cancer treatments.

Researchers discuss the mechanism behind MCL-1 inhibitors, aiming to understand MCL-1 protein stability in cancer cells. The team explores the development of next-generation MCL-1 inhibitors for effective cancer treatment.

Exploration of Diphenyl ditelluride's anticancer activity in human colon cancer cells, including its ability to induce cell cycle arrest, DNA strand breaks, and form covalent complexes with DNA for potential anti-proliferative treatment.

Researchers Diwakar Davar and Roberta Zappasodi discuss the potential of GITR in cancer immunotherapy, its expression on immune cells, preclinical successes, challenges in clinical translation, and understanding immune responses for novel treatments.